| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 Apr 2026 | 27 Mar 2026 |
| Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ending on March 31, 2026 Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 ,inter alia, to consider and approve Update on board meeting (As per BSE Announcement darted on: 23.04.2026) Outcome of Board Meeting held on April 30, 2026 (As per BSE Announcement dated on: 30.04.2026) | ||
| Board Meeting | 30 Jan 2026 | 29 Dec 2025 |
| Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ending on December 31, 2025 Outcome Of Board Meeting Dated January 30, 2026 (As per BSE Announcement dated on: 30.01.2026) Attached (As Per BSE Announcement Dated On : 23.01.2026) | ||
| Board Meeting | 31 Oct 2025 | 24 Oct 2025 |
| Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30 2025; 2. declaration of 2nd Interim Dividend if any on the Equity Shares of the Company for the Financial Year 2025-26; & 3. Consider issuance of bonus shares in accordance with the applicable provisions and subject to approval of Shareholders of the Company. Outcome of Board Meeting held on October 31, 2025 (As per BSE Announcement dated on: 31.10.2025) | ||
| Board Meeting | 31 Jul 2025 | 24 Jul 2025 |
| Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2025 inter alia to consider and approve Un-audited Financial Results for the Quarter ended June 30 2025 and declaration of Interim Dividend if any for FY 2025-26 Attached (As Per BSE Announcement Dated on: 31.07.2025) | ||
Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.
The company declared a third interim dividend of ₹6 per share (60% on a face value of ₹10) for FY25.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
